Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials.

R, Vandenberghe; JO, Rinne; M, Boada; S, Katayama; P, Scheltens; B, Vellas; M, Tuchman; A, Gass; JB, Fiebach; D, Hill; K, Lobello; D, Li; T, McRae; P, Lucas; I, Evans; K, Booth; G, Luscan; BT, Wyman; L, Hua; L, Yang; HR, Brashear; RS, Black

doi:10.1186/s13195-016-0189-7

Public

Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials.

Shared by NobleBlocks on May 12, 2016 • 12:00 AM UTC

Authors:

Vandenberghe R

Rinne JO

Boada M

Abstract

<h4>Background</h4>Our objective was to evaluate the efficacy (clinical and biomarker) and safety of intravenous bapineuzumab in patients with mild to moderate Alzheimer's disease (AD).<h4>Methods</h4>Two of four phase 3, multicenter, randomized, double-blind, placebo-controlled, 18-month trials wer...

Subject

Immunotherapy

Alzheimer’s disease

Clinical Trial

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!